EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Imed Infinity Medical-Limited Partnership (IMED) fair value: what the stock is really worth

As of Oct 9, 2026: fair value of Imed Infinity Medical-Limited Partnership ILS 0.14, price ILS 0.88, upside -83.5%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · Il · ISIN IL0011712309

II Thin data Oct 3, 2026

Imed Infinity Medical-Limited Partnership

IMED · TA

Stretched ValuationStrong overvaluation with only moderate quality.

Quality 53/100
Fair value 0.1445 ILA · Strongly overvalued (−83.5%)
Weak Growth (revenue 3y −18.2 %/yr in ILA)
Negative free cash flow
Trails peers (1/6)
Narrow moat 6/100 · thin data
Thin data
⚠ Dilution
Watch Imed Infinity Medical-Limited Partnership for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

6.96 ILA 0.5340 ILA Fair Value 0.1445 ILA Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 0.5340 ILA – 6.96 ILA · fair‑value band 0.0935 ILA – 0.1785 ILA · the 0.8770 ILA price screens above the 0.1445 ILA fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Imed Infinity Medical-Limited Partnership in your weekly email

Every Wednesday you see whether Imed Infinity Medical-Limited Partnership is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Imed Infinity Medical-Limited Partnership engages in research and development and invests in projects in the medical field in Israel.

Show more

Imed Infinity Medical-Limited Partnership engages in research and development and invests in projects in the medical field in Israel. The company's products include Genoox, a platform for gathering genetic data; biobeat medical smartmonitoring, which provides wireless patient monitoring solutions for both clinical and at-home use; Polaris Quantum Biotech, a system for the computerized design of drugs using quantum computers; and Cynerio, which focuses on ensuring patient safety and data protection by securing the connected medical device ecosystem. It also provides Theranica, which provides migraine treatment through neuromodulation; CytoReason, a computer system that performs modeling of the human body; and Nanomedic, a portable electrospinning device for the treatment and healing of complex burns and wounds. Imed Infinity Medical-Limited Partnership was incorporated in 2020 and is based in Tel Aviv-Yafo, Israel.

Stock analysis

Imed Infinity Medical-Limited Partnership (IMED) currently trades at 0.8770 ILA, while our model-based Fair Value estimate is 0.1445 ILA, 83.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 77/100, which puts the evidence level at low.

Scenario range: 0.0935 ILA (bear) to 0.1785 ILA (bull), the price of 0.8770 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Imed Infinity Medical-Limited Partnership reported revenue of 41.0K ILA in FY2024 versus 75.0K ILA in FY2021, a compound −18.2%/yr. Reported net income was −147K ILA in FY2025.

Key figures

Market cap 6.0M ILA · EPS (TTM) −0.1900 ILA · Return on equity −8.2% · Return on assets (EBIT) −9.7% · Operating margin −2,221% · Revenue (TTM) −417K ILA · Revenue growth (YoY) −97.9% · Free cash flow −368K ILA.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades about 39% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −84%, IMED screens richer than that median.

Fair Value models

Bear 0.0935 ILA Fair Value 0.1445 ILA Bull 0.1785 ILA
Price 0.8770 ILA · Upside -83.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 0.4600 ILA 0.6200 ILA 0.9300 ILA 51
All 1 models by family
Asset-Based
NCAV (Graham) 0.4600 ILA 0.6200 ILA 0.9300 ILA 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 53/100

Of which business quality 53 · Market factors (momentum, volatility) 23

Profitability 4
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 50
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 62
Calm price path (market factor)
Momentum 9
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IMED screens overvalued: fair value 84% below the price. Compare with Veeva Systems Inc →

Compare Imed Infinity Medical-Limited Partnership with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 117 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 53 · Below median
Fair Value upside −83.5% · Bottom 25%
Profitability
Return on assets −7.7% · Bottom 25%
Growth and dividend
Revenue growth −97.9% · Bottom 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 0.31× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $273.33 $300.66 +10% vs IMED
HealthEquity, Inc HQY $88.44 $97.28 +10% vs IMED
Doximity, Inc DOCS $30.50 $33.55 +10% vs IMED
Waystar Holding WAY $26.68 $29.10 +9% vs IMED
Inventurus Knowledge Solutions Limited IKS ₹1,779 ₹1,883 +6% vs IMED
Pro Medicus Limited PME A$161.00 A$84.62 −47% vs IMED
Hinge Health, Inc HNGE $102.90 $51.25 −50% vs IMED
BrightSpring Health Services, Inc BTSG $56.54 $25.86 −54% vs IMED
Privia Health Group PRVA $19.62 $5.02 −74% vs IMED
XtalPi Holdings 2228 HK$7.75 HK$1.50 −81% vs IMED

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Imed Infinity Medical-Limited Partnership · Fair Value
0.1445 ILA −84%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Imed Infinity Medical-Limited Partnership Fair Value". https://www.fairvalue-calculator.com/stock/IMED

Frequently asked questions

Is Imed Infinity Medical-Limited Partnership (IMED) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 0.1445 ILA versus a price of 0.8770 ILA, about −84% upside (overvalued).
What is the fair value of IMED?
Our model-based fair value for Imed Infinity Medical-Limited Partnership is 0.1445 ILA (as of Oct 3, 2026), built from audited fundamentals. The current price: 0.8770 ILA.
What is the quality score of IMED?
Imed Infinity Medical-Limited Partnership has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Imed Infinity Medical-Limited Partnership (IMED)?
Our model-based price target is the fair value of 0.1445 ILA (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 0.0935 ILA, optimistic scenario 0.1785 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Imed Infinity Medical-Limited Partnership stock forecast for 2026?
Our models put fair value at 0.1445 ILA, about −84% upside versus a price of 0.8770 ILA (overvalued). Cautious scenario 0.0935 ILA, optimistic scenario 0.1785 ILA. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Imed Infinity Medical-Limited Partnership (IMED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Imed Infinity Medical-Limited Partnership it is 0.1445 ILA per share (as of Oct 3, 2026), against a price of 0.8770 ILA. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Imed Infinity Medical-Limited Partnership stock overvalued or undervalued in 2026?
As of Oct 3, 2026, IMED trades above its calculated fair value: price 0.8770 ILA, fair value 0.1445 ILA, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMED?
No. The price is what the market pays today (0.8770 ILA); the fair value is what the company's own numbers justify (0.1445 ILA). For Imed Infinity Medical-Limited Partnership the two are 0.7325 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Imed Infinity Medical-Limited Partnership worth?
The market values Imed Infinity Medical-Limited Partnership at about 6.0M ILA (market capitalisation, as of Oct 3, 2026). Per share that is 0.8770 ILA; our models calculate a fair value of 0.1445 ILA per share.
What do the bullish and bearish scenarios say about IMED?
Our models span a range for Imed Infinity Medical-Limited Partnership: cautious scenario 0.0935 ILA, base 0.1445 ILA, optimistic 0.1785 ILA per share (as of Oct 3, 2026, price 0.8770 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Imed Infinity Medical-Limited Partnership (IMED)?
Balance-sheet figures for Imed Infinity Medical-Limited Partnership (as of Oct 3, 2026): return on equity −8.2%. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is IMED from its 52-week high?
Imed Infinity Medical-Limited Partnership trades at 0.8770 ILA, about 39% below its 52-week high of 1.44 ILA and 3% above the low of 0.8530 ILA (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1445 ILA is for.
Which stocks are comparable to Imed Infinity Medical-Limited Partnership?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Imed Infinity Medical-Limited Partnership stock attractive at the current price?
The data as of Oct 3, 2026: price 0.8770 ILA, calculated fair value 0.1445 ILA (−84%), Quality Score 53/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IMED calculated?
We run Imed Infinity Medical-Limited Partnership through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.1445 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Imed Infinity Medical-Limited Partnership itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Imed Infinity Medical-Limited Partnership (IMED)?
The closing price on Oct 9, 2026 was 0.8770 ILA. Our model-based fair value is 0.1445 ILA, about −84% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Imed Infinity Medical-Limited Partnership right now?
The price sits above even our optimistic bull case (0.1785 ILA). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (0.0935 ILA to 0.1785 ILA) leaves room in how you read the outcome.

Key figures of Imed Infinity Medical-Limited Partnership

How large is the market capitalisation of Imed Infinity Medical-Limited Partnership (IMED)?
The market capitalisation of Imed Infinity Medical-Limited Partnership is 6.0M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Imed Infinity Medical-Limited Partnership (IMED)?
Earnings per share at Imed Infinity Medical-Limited Partnership are −0.1900 ILA. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Imed Infinity Medical-Limited Partnership (IMED)?
The return on equity (ROE) of Imed Infinity Medical-Limited Partnership is −8.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Imed Infinity Medical-Limited Partnership (IMED)?
On an EBIT basis the return on assets of Imed Infinity Medical-Limited Partnership is −9.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Imed Infinity Medical-Limited Partnership (IMED)?
The operating margin of Imed Infinity Medical-Limited Partnership is −2,221% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much revenue does Imed Infinity Medical-Limited Partnership (IMED) generate?
Imed Infinity Medical-Limited Partnership generates revenue of −417K ILA (last twelve months). Revenue of the last twelve months (TTM), the most recent full year, not the calendar year.
How fast is revenue growing at Imed Infinity Medical-Limited Partnership (IMED)?
Revenue at Imed Infinity Medical-Limited Partnership is growing −97.9% versus a year earlier (3y avg −18.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Imed Infinity Medical-Limited Partnership (IMED) generate?
The free cash flow of Imed Infinity Medical-Limited Partnership is −368K ILA (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Imed Infinity Medical-Limited Partnership (IMED) hold?
Imed Infinity Medical-Limited Partnership holds more cash than debt, 2.9M ILA net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Imed Infinity Medical-Limited Partnership in the live analysis

One click puts Imed Infinity Medical-Limited Partnership on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.